Galera Therapeutics, INC. (GRTX) SEC Filings — 2025

Filings

• Galera Narrows Losses, Pivots to Breast Cancer After Asset Sale — 10-Q · Nov 13, 2025
• Galera Therapeutics Enters Material Definitive Agreement — 8-K · Oct 27, 2025
• Galera Therapeutics Enters Material Definitive Agreement — 8-K · Oct 21, 2025
• Galera Therapeutics Enters Material Definitive Agreement — 8-K · Sep 3, 2025
• Galera Narrows Losses Amid Strategic Pivot, Faces Going Concern Doubt — 10-Q · Aug 13, 2025
• Galera Therapeutics Files Q1 2025 10-Q — 10-Q · May 15, 2025
• Galera Therapeutics Files 8-K — 8-K · Apr 2, 2025
• Galera Therapeutics Files 2024 10-K — 10-K · Mar 31, 2025
• Galera Therapeutics Files 8-K/A Amendment — 8-K/A · Mar 24, 2025
• Galera Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Feb 25, 2025
• Galera Therapeutics Files Definitive Proxy Statement — DEF 14A · Jan 24, 2025